Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 96Lung Neoplasms 38Neoplasms 10Mesothelioma, Malignant 9Mesothelioma 8Adenocarcinoma of Lung 8Small Cell Lung Carcinoma 7Neoplasm Metastasis 7Thoracic Neoplasms 5Recurrence 5Lung Diseases 5Carcinoma 5Respiratory Tract Neoplasms 4Carcinoma, Bronchogenic 4Brain Neoplasms 4Respiratory Tract Diseases 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Neoplasms by Histologic Type 3NSCLC 3Head and Neck Neoplasms 3Bronchial Neoplasms 3Adenocarcinoma, Bronchiolo-Alveolar 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Neoplasms, Nerve Tissue 2Melanoma 2

Interventions

temsirolimus 1ridaforolimus 1pazopanib 1Surveys and Questionnaires 1Pemetrexed 1Lenalidomide 1Crizotinib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Cancers × Pemetrexed × Clear all
NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Terminated
178 enrolled

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡